Company Insights

ALNY customer relationships

Explore interactive graphBrowse insights index
ALNY customer relationship map

Alnylam Pharmaceuticals: commercial partnerships that fund growth and de-risk R&D

Alnylam monetizes its RNA interference (RNAi) platform through a mix of direct product sales and collaboration/royalty agreements with large pharmaceutical partners. The company sells four commercial products directly in key markets while collecting royalties and milestone and collaboration revenue from partners—most notably Novartis (Leqvio royalties) and ongoing collaborations with Regeneron and Roche—which together act as both a revenue amplifier and a strategic risk-share mechanism. Investors should value Alnylam as a commercial-stage biotech with a hybrid revenue stream: product cashflows plus partner-generated royalties and collaboration fees.

Explore more proprietary relationship intelligence at https://nullexposure.com/.

Why these customer relationships matter to the P&L

Alnylam’s direct product sales underpin gross margin and operating leverage, but partner royalties and collaboration revenue produce episodic, high-margin inflows that materially affect quarterly results. The mix reduces execution risk on late-stage programs while creating concentration and timing risk tied to partner commercialization and milestone schedules. Expect headline volatility around partner-driven revenue lines even as core product revenue shows secular growth.

How Alnylam contracts and where it sells (company-level signals)

Alnylam’s disclosures convey a seller posture: the company both commercializes products directly in major markets and relies on partners in other jurisdictions. The business shows global geographic reach with heavy concentration in North America and Europe; management states the company generates product revenue “primarily in the U.S. and Europe,” while also noting availability of products in more than 70 markets worldwide. Counterparty composition includes large enterprise customers and intermediaries (insurers, PBMs), which increases pricing leverage on the buyer side. These are company-level operating characteristics that shape negotiation dynamics, revenue concentration, and the criticality of partner performance.

Customer relationships: what the filings and transcripts show

Novartis — a royalty engine tied to Leqvio commercialization

Alnylam reported $104 million of royalty revenue for the full year, a 90% increase year-over-year driven by higher Leqvio sales from Novartis, signaling that Leqvio is a meaningful and growing royalty stream for Alnylam in FY2026. According to the Q4 2025 earnings call transcript published on InsiderMonkey (Mar 9, 2026), Leqvio royalties significantly boosted full-year royalty revenue. A separate earnings write-up noted a prior-year license milestone with Novartis that produced a quarter-over-quarter revenue bump, illustrating the lumpy nature of license and milestone recognition tied to Novartis commercialization milestones (TradingView, Mar 9, 2026).
Source: InsiderMonkey Q4 2025 earnings call transcript (Mar 9, 2026); TradingView earnings summary (Mar 9, 2026).
Takeaway: Novartis royalties are a material, high-margin revenue contributor and a driver of FY2026 upside.

Regeneron — ongoing collaboration revenue contributor

Alnylam recognized collaboration revenue from its ongoing work with Regeneron in the fourth quarter and expects that collaboration revenue with Regeneron will be a primary contributor to collaboration and royalty revenue in FY2026, per management commentary. The company’s Q4 2025 remarks cited Regeneron as a key partner whose collaboration payments will drive the majority of collaboration revenue this year (InsiderMonkey, Mar 9, 2026). TradingView’s Q4 earnings coverage also lists Regeneron among partners generating recognized revenue in the quarter (Mar 9, 2026).
Source: InsiderMonkey Q4 2025 earnings call transcript (Mar 9, 2026); TradingView earnings summary (Mar 9, 2026).
Takeaway: Regeneron is a steady collaborator whose payment schedule influences quarterly revenue recognition.

Explore detailed counterparty exposure at https://nullexposure.com/.

Roche — a strategic collaborator with recognized quarterly revenue

Management identified Roche as another active collaboration partner, with collaboration revenues from Roche recognized during the fourth quarter and expected to contribute alongside Regeneron to FY2026 collaboration revenue. Alnylam’s Q4 comments grouped Roche with Regeneron as principal contributors to collaboration revenue, and TradingView’s earnings write-up confirmed recognition of revenue under collaborations with Roche in Q4 (InsiderMonkey and TradingView, Mar 9, 2026).
Source: InsiderMonkey Q4 2025 earnings call transcript (Mar 9, 2026); TradingView earnings summary (Mar 9, 2026).
Takeaway: Roche partnership income is integrated into Alnylam’s near-term revenue outlook and introduces another source of episodic revenue.

Concentration, timing risk and commercial maturity you should price in

  • Concentration risk: A sizable slice of collaboration and royalty revenue is concentrated in a few large partners (Novartis, Regeneron, Roche). That concentration amplifies upside when partners succeed and downside when milestones or commercialization dynamics shift.
  • Timing and lumpy recognition: License milestone payments and royalties create quarter-to-quarter volatility; prior-period license milestones with Novartis illustrate the asymmetric timing of upside.
  • Counterparty leverage: The involvement of large enterprises and payers (insurers and PBMs) indicates a tough pricing environment and potential margin pressure despite high-margin royalty streams.
  • Global commercial footprint with regional concentration: Alnylam is global, but North America and Europe remain the revenue anchors, shaping reimbursement and access risk profiles.

These dynamics create a mixed risk/return profile: durable, high-margin partner revenue that is nevertheless concentrated and lumpy. Investors should underwrite steady product growth while stress-testing partner-dependent lines for timing shifts.

Bottom line and investor action steps

Alnylam’s commercial model combines direct product sales with partner-funded revenue that materially lifts reported results. Novartis royalties from Leqvio are a near-term earnings lever, while collaborations with Regeneron and Roche provide additional high-margin but timing-sensitive inflows. For investors, the thesis is straightforward: value the core product cashflows as a base and treat partner revenue as high-upside, high-volatility add-ons that require active monitoring of partner commercialization and milestone calendars.

Further reading and counterparty analytics are available at https://nullexposure.com/.

If you evaluate provider risk or run scenario models on partner-dependent biotech revenue, check our coverage at https://nullexposure.com/ for ongoing updates and signal-driven relationship intelligence.